4DMedical Files FDA Submission for Revolutionary CT:VQ™ Lung Imaging Software

4DMedical Ltd ( (AU:4DX) ) has issued an update.

4DMedical Limited has filed an FDA 510(k) submission for its CT:VQ™ software, a groundbreaking non-contrast CT-based lung imaging product that assesses both ventilation and perfusion in the lungs. This innovation addresses clinical and logistical challenges associated with traditional nuclear VQ imaging, offering higher resolution and accessibility by leveraging existing CT infrastructure. The company anticipates capturing the entire market of one million annual nuclear VQ scans in the U.S., with potential global market expansion. CT:VQ™ is expected to drive long-term growth in demand for lung assessments, transforming pulmonary care by making comprehensive evaluations more accessible, even in facilities without nuclear medicine capabilities.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is a global leader in respiratory imaging technology, specializing in innovative lung imaging solutions. The company focuses on developing advanced imaging software products that enhance the assessment of lung health, aiming to improve diagnostic accuracy and accessibility in the healthcare industry.

Average Trading Volume: 939,957

Technical Sentiment Signal: Sell

Current Market Cap: A$117.1M

Learn more about 4DX stock on TipRanks’ Stock Analysis page.